FDA policy on direct-to-consumer Rx drug ads
FDA's working group on direct-to-consumer advertising of prescription drugs will meet in the "near future" to review recent revisions made in a draft document outlining the agency's official policy. Before being issued for comment in the Federal Register, the policy must be approved by Center for Drug Evaluation and Research Director Carl Peck and FDA Acting Commissioner James Benson. FDA's Division of Drug Advertising and Labeling recently submitted documents to Rep. Dingell regarding FDA's position on direct-to-consumer prescription ads ("The Pink Sheet" April 9, p. 5).
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.